

Pere Domingo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7726017/pere-domingo-publications-by-citations.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

375 papers	9,495 citations	50 h-index	79 g-index
418 ext. papers	11,130 ext. citations	5.9 avg, IF	5.54 L-index

#	Paper	IF	Citations
375	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. <i>Nature Medicine</i> , 2010 , 16, 460-5	50.5	441
374	Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2013 , 13, 927-35	25.5	290
373	Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 2003 , 349, 1036-46	59.2	268
372	Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. <i>Aids</i> , 2002 , 16, 209-18	3.5	213
371	Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naïve, HIV-1-infected adults: 48-week results from the ASSERT study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1989), 2010 , 55, 10-17	3.1	185
370	A randomized trial of the discontinuation of primary and secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. <i>New England Journal of Medicine</i> , 2001 , 344, 159-67	59.2	176
369	Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. <i>Aids</i> , 1999 , 13, 2261-7	3.5	171
368	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 499-518	27.4	154
367	Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. <i>Clinical Infectious Diseases</i> , 2002 , 34, 838-46	11.6	152
366	Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. <i>American Journal of Medicine</i> , 2001 , 110, 605-9	2.4	120
365	Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1047-52	11.6	113
364	Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001 , 27, 229-36	3.1	113
363	Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2015 , 15, 785-92	25.5	111
362	Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. <i>Cancer</i> , 2010 , 116, 5306-15	6.4	104
361	Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. <i>Clinical Infectious Diseases</i> , 2004 , 38, 565-71	11.6	102
360	Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. <i>Antiviral Therapy</i> , 2012 , 17, 355-64	1.6	98
359	Group B streptococcal meningitis in adults: report of twelve cases and review. <i>Clinical Infectious Diseases</i> , 1997 , 25, 1180-7	11.6	98

358	Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(gamma):RXR heterodimers: comparison with other polyunsaturated fatty acids. <i>Journal of Leukocyte Biology</i> , 2008 , 84, 1172-82	6.5	94
357	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. <i>Aids</i> , 2012 , 26, 2315-26	3.5	92
356	HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy. <i>Antiviral Therapy</i> , 2006 , 11, 729-740	1.6	90
355	Sensitivity and specificity of nested and real-time PCR for the detection of <i>Pneumocystis jiroveci</i> in clinical specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006 , 56, 153-60	2.9	86
354	FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. <i>Clinical Nutrition</i> , 2017 , 36, 861-868	5.9	81
353	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). <i>EBioMedicine</i> , 2020 , 58, 102887	8.8	78
352	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2014 , 14, 590-9	25.5	75
351	A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. <i>Diabetologia</i> , 2013 , 56, 2524-37	10.3	75
350	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. <i>Clinical Infectious Diseases</i> , 2017 , 65, 712-718	11.6	71
349	Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 29-36	3.1	71
348	Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naïve HIV-1 patients: the ARTEN Trial. <i>Antiviral Therapy</i> , 2011 , 16, 339-48	1.6	69
347	Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1017-23	11.6	69
346	Infectious pulmonary nodules in immunocompromised patients: usefulness of computed tomography in predicting their etiology. <i>Journal of Computer Assisted Tomography</i> , 2003 , 27, 461-8	2.2	68
345	Primary meningococcal conjunctivitis: report of 21 patients and review. <i>Clinical Infectious Diseases</i> , 1990 , 12, 838-47	11.6	68
344	Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. <i>Trends in Pharmacological Sciences</i> , 2005 , 26, 88-93	13.2	66
343	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. <i>Aids</i> , 2007 , 21, 169-78	3.5	65
342	Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 49, 26-31	3.1	63
341	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005 , 19, 569-75	3.5	62

340	Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010 , 1801, 392-9	5	61
339	Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. <i>American Journal of Medicine</i> , 2002 , 112, 19-25	2.4	61
338	Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. <i>Aids</i> , 2012 , 26, 475-81	3.5	60
337	HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. <i>Antiviral Therapy</i> , 2006 , 11, 729-40	1.6	59
336	Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. <i>Aids</i> , 2006 , 20, 1407-14	3.5	58
335	Adipose tissue biology and HIV-infection. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011 , 25, 487-99	6.5	56
334	A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 1505-14	1.6	56
333	In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3824-32	5.9	55
332	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor-Experienced Patients With HIV-Associated Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 229-236	3.1	55
331	Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1668-1676	11.6	55
330	Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. <i>Archives of Neurology</i> , 1999 , 56, 609-12		54
329	9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. <i>Journal of Immunology</i> , 2007 , 179, 4188-9	5.3	53
328	96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naïve, HIV-1-infected adults: ASSERT study. <i>Antiviral Therapy</i> , 2013 , 18, 905-13	1.6	52
327	Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 690-7	5.1	52
326	Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. <i>Journal of Infectious Diseases</i> , 2001 , 184, 1197-201	7	51
325	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. <i>Aids</i> , 2001 , 15, 1701-6	3.5	49
324	Semiinvasive pulmonary aspergillosis in chronic obstructive pulmonary disease: radiologic and pathologic findings in nine patients. <i>American Journal of Roentgenology</i> , 2000 , 174, 51-6	5.4	48
323	Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. <i>Clinical Infectious Diseases</i> , 2013 , 57, 112-21	11.6	45

322	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. <i>Aids</i> , 2017 , 31, 2503-2514	3.5	45
321	Differential gene expression indicates that Buffalo hump is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. <i>Aids</i> , 2008 , 22, 575-84	3.5	44
320	Morbidity associated with long-term use of totally implantable ports in patients with AIDS. <i>Clinical Infectious Diseases</i> , 1999 , 29, 346-51	11.6	44
319	The spectrum of acute bacterial meningitis in elderly patients. <i>BMC Infectious Diseases</i> , 2013 , 13, 108	4	42
318	Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009. <i>AIDS Research and Therapy</i> , 2011 , 8, 22	3	42
317	Bilateral Bell palsy and acute HIV type 1 infection: report of 2 cases and review. <i>Clinical Infectious Diseases</i> , 2007 , 44, e57-61	11.6	42
316	HIV and antiretroviral therapy-related fat alterations. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 48	51.1	41
315	Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 321-9	1.6	41
314	Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. <i>Current HIV Research</i> , 2010 , 8, 545-53	1.3	40
313	Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. <i>Aids</i> , 2010 , 24, 2629-37	3.5	40
312	Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008 , 62, 34-43	2.9	40
311	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1571-1577	11.6	40
310	Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. <i>AIDS Reviews</i> , 2012 , 14, 112-23	1.5	40
309	The future of antiretroviral therapy: challenges and needs. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 827-35	5.1	39
308	Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. <i>Antiviral Therapy</i> , 2012 , 17, 1011-20	1.6	39
307	Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 441, 599-604	5.1	39
306	Air trapping in primary Sjögren syndrome: correlation of expiratory CT with pulmonary function tests. <i>Journal of Computer Assisted Tomography</i> , 1999 , 23, 169-73	2.2	39
305	Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 681-92	6.2	38

304	Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. <i>Aids</i> , 2015 , 29, 1205-15	3.5	37
303	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. <i>Aids</i> , 2006 , 20, 2075-80	3.5	37
302	Discontinuation of primary and secondary <i>Toxoplasma gondii</i> prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. <i>Clinical Infectious Diseases</i> , 2006 , 43, 79-89	11.6	36
301	Erythema nodosum and hepatitis C. <i>Lancet, The</i> , 1990 , 336, 1377	4.0	36
300	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3368-71	5.1	35
299	Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. <i>Antiviral Research</i> , 2011 , 91, 112-9	10.8	35
298	Air-leak syndromes in hematopoietic stem cell transplant recipients with chronic GVHD: high-resolution CT findings. <i>Journal of Thoracic Imaging</i> , 2007 , 22, 335-40	5.6	35
297	Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. <i>Aids</i> , 2004 , 18, 1475-8	3.5	35
296	Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 527-31	3.1	35
295	Cutaneous angiomas in POEMS syndrome. <i>Journal of the American Academy of Dermatology</i> , 1985 , 12, 961-4	4.5	35
294	Spontaneous gram-negative bacillary meningitis in adult patients: characteristics and outcome. <i>BMC Infectious Diseases</i> , 2013 , 13, 451	4	34
293	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. <i>Aids</i> , 2011 , 25, 1683-90	3.5	34
292	Acute Q fever in adult patients: report on 63 sporadic cases in an urban area. <i>Clinical Infectious Diseases</i> , 1999 , 29, 874-9	11.6	34
291	Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 2003 , 139, 81-9	8	33
290	Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. <i>AIDS Reviews</i> , 2014 , 16, 199-212	1.5	33
289	Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). <i>Clinical Infectious Diseases</i> , 2009 , 49, 892-900	11.6	32
288	Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 582-7	3.1	32
287	Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , 2016 , 17, 590-600	2.7	31

286	Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy. <i>Lancet, The</i> , 1997 , 349, 1554-5	40	31
285	Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 64, 142-8	3.1	30
284	The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 234-45	5.1	30
283	Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines. <i>Antiviral Research</i> , 2016 , 132, 59-65	10.8	30
282	Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1083-92	11.6	29
281	Pharmacogenetics of adverse effects due to antiretroviral drugs. <i>AIDS Reviews</i> , 2010 , 12, 15-30	1.5	29
280	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw059	1	28
279	Hepatitis C virus and human immunodeficiency virus coinfection in Spain. <i>Journal of Infection</i> , 2003 , 47, 117-24	18.9	28
278	Pneumococcal bacteraemia in immunocompetent adults. <i>Lancet, The</i> , 1991 , 337, 57	40	28
277	Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 28, 14-8	3.1	27
276	Peak bone mass in young HIV-infected patients compared with healthy controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, 207-12	3.1	26
275	Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. <i>Immunobiology</i> , 2017 , 222, 989-997	3.4	25
274	Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. <i>Clinical Infectious Diseases</i> , 2015 , 60, 811-20	11.6	25
273	Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1033-40	11.6	25
272	HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. <i>Current HIV Research</i> , 2009 , 7, 597-600	1.3	25
271	The changing face of HIV/AIDS in treated patients. <i>Current HIV Research</i> , 2009 , 7, 365-77	1.3	25
270	Clinical utility of maraviroc. <i>Clinical Drug Investigation</i> , 2011 , 31, 527-542	3.2	24
269	First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 1348-58	5.1	24

268	HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors. <i>Current HIV Research</i> , 2007 , 5, 467-73	1.3	24
267	Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 132-8	3.1	24
266	Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1514-9	11.6	24
265	Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 317-23	3.1	24
264	Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. <i>Aids</i> , 2004 , 18, 959-60	3.5	23
263	Acute appendicitis complicating infectious mononucleosis: case report and review. <i>Clinical Infectious Diseases</i> , 1990 , 12, 297-302	11.6	23
262	Fat Distribution and Metabolic Abnormalities in HIV-Infected Patients on First Combination Antiretroviral Therapy Including Stavudine or Zidovudine: Role of Physical Activity as a Protective Factor. <i>Antiviral Therapy</i> , 2003 , 8, 223-231	1.6	23
261	Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. <i>Cytokine</i> , 2012 , 58, 253-60	4	22
260	HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes. <i>Antiviral Therapy</i> , 2012 , 17, 529-40	1.6	22
259	Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 385-7	3.1	22
258	Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 598-606	3.1	22
257	The changing pattern of bacterial meningitis in adult patients at a large tertiary university hospital in Barcelona, Spain (1982-2010). <i>Journal of Infection</i> , 2013 , 66, 147-54	18.9	21
256	Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. <i>Cytokine</i> , 2013 , 61, 808-15	4	21
255	Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. <i>PLoS ONE</i> , 2014 , 9, e89088	3.7	21
254	Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. <i>PLoS ONE</i> , 2013 , 8, e70201	3.7	21
253	Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3369-75	5.9	21
252	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2479-86	5.1	21
251	Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 17-22	3.1	21

250	Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. <i>AIDS Reviews</i> , 2010 , 12, 3-14	1.5	21
249	Effects of Metformin Or Gemfibrozil on the Lipodystrophy of HIV-Infected Patients Receiving Protease Inhibitors. <i>Antiviral Therapy</i> , 2003 , 8, 403-410	1.6	21
248	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. <i>HIV Medicine</i> , 2019 , 20, 237-247	2.7	20
247	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2104-7	5.1	20
246	Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. <i>Antiviral Therapy</i> , 2012 , 17, 337-46	1.6	20
245	Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2195-203	5.1	20
244	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005 , 77, 23-8	19.7	20
243	Evans® syndrome triggered by recombinant hepatitis B vaccine. <i>Clinical Infectious Diseases</i> , 1992 , 15, 1051	11.6	20
242	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1139-45	5.1	19
241	Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1390-6	5.1	19
240	Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 152-60	3.1	19
239	Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 57, 16-23	3.1	19
238	Methicillin-resistant Staphylococcus aureus meningitis in adults: a multicenter study of 86 cases. <i>Medicine (United States)</i> , 2012 , 91, 10-17	1.8	19
237	Reverse Transcriptase Inhibitors Alter Uncoupling Protein-1 and Mitochondrial Biogenesis in Brown Adipocytes. <i>Antiviral Therapy</i> , 2005 , 10, 515-526	1.6	19
236	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 597-606	11.6	18
235	Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1653-9	5.1	18
234	Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. <i>PLoS ONE</i> , 2014 , 9, e114142	3.7	18
233	Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 253-60	3.1	18

232	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 358-62	5.1	18
231	Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2987-93	5.9	18
230	Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 527-34	3.1	18
229	Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 131-7	3.1	18
228	Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. <i>BMC Medical Genetics</i> , 2010 , 11, 63	2.1	18
227	Meningococcal meningitis during penicillin therapy for meningococemia. <i>Clinical Infectious Diseases</i> , 1997 , 25, 1479	11.6	18
226	The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes. <i>Aids</i> , 2008 , 22, 893-6	3.5	18
225	Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort. <i>PLoS ONE</i> , 2015 , 10, e0145701	3.7	18
224	Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19. <i>Frontiers in Medicine</i> , 2020 , 7, 557	4.9	18
223	Fat tissue measurements by dual-energy x-ray absorptiometry: cross-calibration of 3 different fan-beam instruments. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 212-22	3.5	17
222	Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. <i>Clinical Infectious Diseases</i> , 2011 , 52, 662-70	11.6	17
221	Drug safety profile of integrase strand transfer inhibitors. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 431-45	4.1	16
220	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1130-8	5.1	16
219	Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. <i>HIV Clinical Trials</i> , 2012 , 13, 61-9		16
218	Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. <i>Aids</i> , 2007 , 21, 367-9	3.5	16
217	Altered expression of master regulatory genes of adipogenesis in lipomas from patients bearing tRNA(Lys) point mutations in mitochondrial DNA. <i>Molecular Genetics and Metabolism</i> , 2006 , 89, 283-5	3.7	16
216	Lack of association of SDF-1 3' variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 276-9	3.1	16
215	Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. <i>Clinical Infectious Diseases</i> , 1995 , 21, 1488-91	11.6	16

214	Bacterial meningitis with "normal" cerebrospinal fluid in adults: a report on five cases. <i>Scandinavian Journal of Infectious Diseases</i> , 1990 , 22, 115-6		16
213	Not all COVID-19 pandemic waves are alike. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1040.e7-1040.e10		16
212	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofx258	1	16
211	Altered Expression of Nucleoside Transporter Genes (SLC28 and SLC29) in Adipose Tissue from HIV-1 Infected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 853-864	1.6	16
210	Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. <i>Aging Cell</i> , 2018 , 17, e12822	9.9	15
209	Thymidine kinase 2 deficiency-induced mitochondrial DNA depletion causes abnormal development of adipose tissues and adipokine levels in mice. <i>PLoS ONE</i> , 2011 , 6, e29691	3.7	15
208	Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. <i>HIV Clinical Trials</i> , 2011 , 12, 313-22		15
207	Immune reconstitution in severely immunosuppressed antiretroviral-naïve HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 747-57	1.6	15
206	Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer. <i>PLoS ONE</i> , 2012 , 7, e47755	3.7	15
205	Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. <i>Open AIDS Journal</i> , 2008 , 2, 26-38	0.6	15
204	Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?. <i>AIDS Reviews</i> , 2004 , 6, 169-80	1.5	15
203	A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2018 , 32, 565-573	3.5	14
202	Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 85-92	6.2	14
201	Management of complications associated with totally implantable ports in patients with AIDS. <i>AIDS Patient Care and STDs</i> , 2001 , 15, 7-13	5.8	14
200	Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3371-8	3.3	14
199	Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. <i>HIV Clinical Trials</i> , 2015 , 16, 57-65		13
198	Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1453-8	5.1	13
197	Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. <i>Antiviral Therapy</i> , 2013 , 18, 125-30	1.6	13

196	Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 390-6	3.1	13
195	Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. <i>Aids</i> , 2008 , 22, 377-84	3.5	13
194	Epidemiological trends of HIV infection in Spain. <i>Aids</i> , 2002 , 16, 2496-2499	3.5	13
193	Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. <i>Antiviral Therapy</i> , 2003 , 8, 223-31	1.6	13
192	Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial. <i>Antiviral Therapy</i> , 2005 , 10, 825-832	1.6	13
191	Liver Triglyceride Content in HIV-1-Infected Patients on Combination Antiretroviral Therapy Studied with ¹ H-MR Spectroscopy. <i>Antiviral Therapy</i> , 2007 , 12, 195-204	1.6	13
190	Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infected patients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study. <i>Cytokine</i> , 2018 , 105, 73-79	4	12
189	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. <i>Atherosclerosis</i> , 2018 , 273, 28-36	3.1	12
188	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 69, 206-15	3.1	12
187	HIV-1 infection and the PPAR β -dependent control of adipose tissue physiology. <i>PPAR Research</i> , 2009 , 2009, 607902	4.3	12
186	Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1428-35	5.9	12
185	Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08). <i>European Journal of Public Health</i> , 2012 , 22, 802-8	2.1	12
184	Lateral decubitus CT: a useful adjunct to standard inspiratory-expiratory CT for the detection of air-trapping. <i>American Journal of Roentgenology</i> , 2000 , 174, 528-30	5.4	12
183	PPAR γ Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy. <i>Current HIV Research</i> , 2009 , 7, 533-40	1.3	12
182	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018 , 32, 1995-2004	3.5	12
181	Very low level viraemia and risk of virological failure in treated HIV-1-infected patients. <i>HIV Medicine</i> , 2017 , 18, 196-203	2.7	11
180	A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 66, 457-65	3.1	11
179	Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 1061-5	1.6	11

178	Polyradiculoneuropathy associated to human herpesvirus 2 in an HIV-1-infected patient (Elsberg syndrome): case report and literature review. <i>Sexually Transmitted Diseases</i> , 2010 , 37, 123-5	2.4	11
177	Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome. <i>PLoS ONE</i> , 2010 , 5, e13896	3.7	11
176	The Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell Lineages. <i>PLoS ONE</i> , 2015 , 10, e0136571	3.7	11
175	Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. <i>Clinical Immunology</i> , 2021 , 223, 108639		11
174	Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. <i>Antiviral Therapy</i> , 2007 , 12, 853-63	1.6	11
173	High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients. <i>Metabolism: Clinical and Experimental</i> , 2017 , 71, 163-170	12.7	10
172	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 361-71	0.9	10
171	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014 , 32, 447-58	0.9	10
170	Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. <i>Aids</i> , 2012 , 26, 2165-74	3.5	10
169	Impaired expression of mitochondrial and adipogenic genes in adipose tissue from a patient with acquired partial lipodystrophy (Barraquer-Simons syndrome): a case report. <i>Journal of Medical Case Reports</i> , 2008 , 2, 284	1.2	10
168	Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. <i>Aids</i> , 2005 , 19, 1385-91	3.5	10
167	Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 4421-3	9.7	10
166	Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less. <i>Aids</i> , 2004 , 18, 1727-9	3.5	10
165	Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 37, 1276-81	3.1	10
164	Cerebrospinal fluid adenosine deaminase levels in a patient with cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 1992 , 15, 1061-2	11.6	10
163	Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy. <i>PLoS ONE</i> , 2013 , 8, e57347	3.7	10
162	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. <i>Lancet HIV</i> , 2021 , 8, e701-e710	7.8	10
161	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 517-23	0.9	10

160	Efavirenz-induced leukocytoclastic vasculitis. <i>Archives of Internal Medicine</i> , 2002 , 162, 355-6		10
159	Does choice of antiretroviral drugs matter for inflammation?. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 389-396	3.8	9
158	Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV. <i>International Journal of Obesity</i> , 2020 , 44, 1970-1973	5.5	9
157	Bacterial meningitis: the end of the beginning?. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 271-2	25.5	9
156	Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. <i>BMC Women's Health</i> , 2011 , 11, 36	2.9	9
155	Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. <i>HIV Clinical Trials</i> , 2009 , 10, 432-8		9
154	No relationship between TNF- β genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 143-52	1.6	9
153	HIV type-1 transgene expression in mice alters adipose tissue and adipokine levels: towards a rodent model of HIV type-1 lipodystrophy. <i>Antiviral Therapy</i> , 2010 , 15, 1021-8	1.6	9
152	Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. <i>Scandinavian Journal of Infectious Diseases</i> , 1996 , 28, 185-7		9
151	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 844-849	5.1	9
150	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015 , 33, 544-56	0.9	8
149	Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/EKlotho System. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	8
148	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. <i>Journal of Infection</i> , 2012 , 64, 204-11	18.9	8
147	Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. <i>Aids</i> , 2015 , 29, 1493-504	3.5	8
146	Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2013-9	5.1	8
145	Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 473-85	4.1	8
144	Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study. <i>HIV Clinical Trials</i> , 2012 , 13, 131-41		8
143	Lipodystrophy in HIV-1-infected patients. <i>Lancet, The</i> , 1999 , 354, 868	40	8

142	Disseminated cytomegalovirus infection in an immunocompetent adult successfully treated with ganciclovir. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 523-5		8
141	Trimethoprim-sulfamethoxazole-induced renal tubular acidosis in a patient with AIDS. <i>Clinical Infectious Diseases</i> , 1995 , 20, 1435-7	11.6	8
140	Tuberculous pulmonary gangrene: report of a case and review. <i>Clinical Infectious Diseases</i> , 1994 , 18, 243-51.6	5.6	8
139	Liver involvement in acute Q fever. <i>Chest</i> , 1988 , 94, 895-6	5.3	8
138	Neuropsychological deficits in patients with cognitive complaints after COVID-19.. <i>Brain and Behavior</i> , 2022 , e2508	3.4	8
137	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. <i>Aids</i> , 2018 , 32, 2807-2819	3.5	8
136	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. <i>HIV Medicine</i> , 2019 , 20, 264-273	2.7	7
135	Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1825-32	5.1	7
134	Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 713-7	1.6	7
133	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 206-9	5.1	7
132	Moraxella catarrhalis bacteraemia in an immunocompetent adult. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 95		7
131	Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists. <i>European Journal of Rheumatology</i> , 2020 , 7, S107-S109	1.7	7
130	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 195-202	0.9	7
129	Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. <i>Antiviral Therapy</i> , 2005 , 10, 515-26	1.6	7
128	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 516.e1-516.e18	0.9	6
127	Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfecting subjects. <i>Antiviral Research</i> , 2014 , 104, 59-61	10.8	6
126	Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 81-101	5.5	6
125	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017 , 35, 88-99	0.9	6

124	An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1749-60	4	6
123	Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1055-64	4	6
122	Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40:01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. <i>PLoS ONE</i> , 2013 , 8, e67035	3.7	6
121	Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1365-82	5.5	6
120	Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. <i>Antiviral Therapy</i> , 2010 , 15, 803-16	1.6	6
119	Successful liver transplantation using a polycystic donor liver. <i>Journal of Hepatology</i> , 1997 , 26, 1428	13.4	6
118	Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 261-7	4.2	6
117	Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase. <i>Annals of Clinical Biochemistry</i> , 1999 , 36 (Pt 5), 601-8	2.2	6
116	Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3510-3514	5.1	6
115	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 373-379	0.9	6
114	Tolerability of Current Antiretroviral Single-Tablet Regimens. <i>AIDS Reviews</i> , 2018 , 20, 141-149	1.5	6
113	Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. <i>Antiviral Therapy</i> , 2007 , 12, 195-203	1.6	6
112	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 29-32	1.6	5
111	Characteristics and outcome of spontaneous bacterial meningitis in patients with cancer compared to patients without cancer. <i>Medicine (United States)</i> , 2017 , 96, e6899	1.8	5
110	Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. <i>Lancet Infectious Diseases</i> , 2019 , 19, e284-e294	25.5	5
109	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 268-276	0.9	5
108	Executive summary of the consensus document on osteoporosis in HIV-infected individuals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 312-314	0.9	5
107	Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011 , 29, 482-9	0.9	5

106	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2012 , 17, 577-83	1.6	5
105	Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010 , 28, 266-72	0.9	5
104	Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 189-96	5.1	5
103	Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1871-84	4	5
102	Absence of mutations in exon 8 of the gene in combination antiretroviral therapy-associated partial lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 457-8	3.1	5
101	Acute Bacterial Meningitis in the Elderly. <i>Archives of Internal Medicine</i> , 1990 , 150, 1546		5
100	Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. <i>Aids</i> , 2002 , 16, 1299-301	3.5	5
99	Linezolid for therapy of meningitis: a cohort study of 26 patients. <i>Infectious Diseases</i> , 2020 , 52, 808-815	3.1	5
98	High circulating SDF-1 and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. <i>EBioMedicine</i> , 2020 , 62, 103077	8.8	5
97	Drug therapies for HIV-related metabolic disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1327-38	3.8	5
96	Drug-drug interactions when treating HIV-related metabolic disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 787-802	5.5	4
95	Glycoprotein Profile Assessed by H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
94	Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. <i>Aids</i> , 2018 , 32, 1309-1316	3.5	4
93	Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 16-20	0.9	4
92	Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study. <i>Clinical Nutrition</i> , 2018 , 37, 1340-1347	5.9	4
91	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 151-159	0.9	4
90	Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naïve patients aged 50 years or older in Spain: The TRIP study. <i>HIV Clinical Trials</i> , 2015 , 16, 43-8		4
89	Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients. <i>BioMed Research International</i> , 2014 , 2014, 823058	3	4

88	Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients. <i>Current HIV Research</i> , 2010 , 8, 467-70	1.3	4
87	Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 931-4	1.6	4
86	Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 114-6	3.1	4
85	Consumptive coagulopathy associated with aortic aneurysm. <i>American Journal of Medicine</i> , 1987 , 83, 189-90	2.4	4
84	HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels. <i>PLoS ONE</i> , 2015 , 10, e0144789	3.7	4
83	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. <i>Trials</i> , 2021 , 22, 808	2.8	4
82	FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). <i>PLoS ONE</i> , 2021 , 16, e0252144	3.7	4
81	Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2171-2176	5.1	4
80	Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort). <i>Aids</i> , 2002 , 16, 2496-9	3.5	4
79	Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms.. <i>Journal of Neurology</i> , 2022 , 1	5.5	4
78	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrologia</i> , 2019 , 39, 497-505	1.5	3
77	Improved adipose tissue function with initiation of protease inhibitor-only ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3212-3221	5.1	3
76	Switching antiretroviral regimes for the treatment of HIV: safety implications. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1349-60	4.1	3
75	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1346-51	5.1	3
74	Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy. <i>Brazilian Journal of Infectious Diseases</i> , 2013 , 17, 444-9	2.8	3
73	ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19814	5.4	3
72	Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. <i>HIV Clinical Trials</i> , 2013 , 14, 204-15		3
71	Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1462-9	5.1	3

70	Disseminated cryptococcosis resembling millary tuberculosis in an HIV-1-infected patient. <i>Lancet Infectious Diseases, The</i> , 2005 , 5, 189	25.5	3
69	Brain biopsy for intracranial mass lesions in AIDS. <i>Lancet, The</i> , 1993 , 341, 242-243	40	3
68	Cellulitis after axillary lymph node dissection. <i>American Journal of Medicine</i> , 1994 , 97, 201-2	2.4	3
67	Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy. <i>Revista Clinica Espanola</i> , 2020 , 220, 149-154	0.7	3
66	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3334-3343	5.1	3
65	Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus. <i>BMC Infectious Diseases</i> , 2020 , 20, 292	4	3
64	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1127-1141	4	3
63	Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. <i>Lancet HIV,the</i> , 2021 , 8, e463-e473	7.8	3
62	Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA [®] , Because of a Previous Intolerance to cART. PRO-STR Study. <i>Current HIV Research</i> , 2018 , 16, 425-435	1.3	2
61	Expression of human and mouse adenine nucleotide translocase (ANT) isoform genes in adipogenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2015 , 64, 34-44	5.6	2
60	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1955-1960	5.1	2
59	HIV/HCV Coinfection in Spain: Prevalence and Patient Characteristics. <i>Journal of Hepatology</i> , 2016 , 64, S617	13.4	2
58	Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 149-58	0.9	2
57	IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status. <i>Scientific Reports</i> , 2019 , 9, 15722	4.9	2
56	Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19773	5.4	2
55	Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. <i>Expert Review of Endocrinology and Metabolism</i> , 2011 , 6, 21-30	4.1	2
54	Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 165-70	1.6	2
53	Polymorphisms in the 3' untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression. <i>Aids</i> , 2007 , 21, 891-3	3.5	2

52	Inmunoterapia y vacunas terapéuticas en la infección por VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2005 , 23, 84-94	0.9	2
51	Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 382-3	3.1	2
50	99mTc-HMPAO SPET: a method to study visual loss in cryptococcal meningitis. <i>Acta Neurologica Scandinavica</i> , 2000 , 102, 340-1	3.8	2
49	Sore throat, antibiotics, and progression to meningococcal disease. <i>Lancet, The</i> , 1995 , 345, 460	4.0	2
48	Multiple Myeloma With Polyneuropathy and Coagulopathy. <i>Archives of Internal Medicine</i> , 1986 , 146, 2089		2
47	Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19.. <i>PLoS ONE</i> , 2022 , 17, e0262777	3.7	2
46	Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission.. <i>Scientific Reports</i> , 2022 , 12, 640	4.9	2
45	Alpha variant SARS-CoV-2 infection: How it all starts. <i>EBioMedicine</i> , 2021 , 74, 103703	8.8	2
44	Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study. <i>Current HIV Research</i> , 2012 , 10, 673-8	1.3	2
43	Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. <i>Diagnostics</i> , 2021 , 11,	3.8	2
42	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2380-2393	5.1	2
41	Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease. <i>BMJ Case Reports</i> , 2018 , 2018,	0.9	2
40	Consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014 , 34 Suppl 2, 1-81	1.5	2
39	Neisseria meningitidis and purpura fulminans in a woman with chronic liver disease. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 459	25.5	1
38	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019 , 37, 151-159	0.1	1
37	Atazanavir dose reduction: one size does not fit all. <i>Lancet HIV,the</i> , 2016 , 3, e334-e335	7.8	1
36	ART regimes and fat: the healing hand wielding the sword. <i>Lancet HIV,the</i> , 2017 , 4, e2-e3	7.8	1
35	Hypertrophied facial fat in an HIV-1-infected patient after autologous transplantation from Buffalo hump retains a partial brown-fat-like molecular signature. <i>Antiviral Therapy</i> , 2013 , 18, 635-9	1.6	1

34	Immunotherapy and therapeutic vaccines in HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2005 , 23, 95-104	0.9	1
33	Bacterial meningitis and the painful eye. <i>Lancet, The</i> , 1996 , 347, 122-3	4.0	1
32	Invasive pneumococcal disease in HIV-1 infected patients. <i>Lancet, The</i> , 1996 , 347, 1414	4.0	1
31	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naïve Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). <i>Clinical Infectious Diseases</i> , 2021 , 73, e1991-e1999	11.6	1
30	Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. <i>Medicine (United States)</i> , 2021 , 100, e25923	1.8	1
29	Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. <i>HIV Medicine</i> , 2016 , 17, 340-9	2.7	1
28	Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up. <i>HIV Research and Clinical Practice</i> , 2019 , 20, 151-155	1.7	1
27	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 86, 248-257	3.1	1
26	Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021 , 9, 758347	6	1
25	Análisis de minimización de costes de diferentes combinaciones de inhibidores de la transcriptasa inversa análogos de nucleósidos asociados a acontecimientos adversos en pacientes infectados por el VIH-1. <i>Pharmacoeconomics - Spanish Research Articles</i> , 2007 , 4, 25-36		0
24	Absence of Mutations in Exon 8 of the LMNA Gene in Combination Antiretroviral Therapy-Associated Partial Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 457-458	3.1	0
23	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naïve Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab595	1	0
22	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3517-3524	5.1	0
21	Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. <i>PLoS ONE</i> , 2021 , 16, e0249515	3.7	0
20	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021 , 35, 2025-2033	3.3	0
19	Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. <i>BMJ Open</i> , 2021 , 11, e051237	3	0
18	Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy. <i>HIV Clinical Trials</i> , 2016 , 17, 89-95		0
17	Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 79, 481-490	3.1	0

16	Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. <i>BMC Public Health</i> , 2021 , 21, 1596	4.1	o
15	Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT.. <i>European Radiology</i> , 2022 , 1	8	o
14	Pulmonary Infections in People Living with HIV.. <i>Radiologic Clinics of North America</i> , 2022 , 60, 507-520	2.3	o
13	Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. <i>HIV Clinical Trials</i> , 2017 , 18, 49-53		
12	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017 , 35, 88-99	0.1	
11	Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018 , 36, 16-20	0.1	
10	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2012 , 17, 597	1.6	
9	Antiagregantes plaquetarios y su influencia en la estancia hospitalaria y consumo de recursos sanitarios en pacientes ancianos con fractura de fémur. <i>Revista De Calidad Asistencial: Órgano De La Sociedad Española De Calidad Asistencial</i> , 2005 , 20, 251-255		
8	Aerosolized pentamidine prophylaxis of <i>Pneumocystis carinii</i> pneumonia in HIV-infected patients. <i>American Journal of Medicine</i> , 1995 , 98, 101-2	2.4	
7	Antibiotic prophylaxis and endocarditis. <i>Lancet, The</i> , 1992 , 339, 738	4.0	
6	Meningococemia 2001 , 473-502		
5	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrología</i> , 2019 , 39, 497-505	0.4	
4	The pharmacological management of cardiovascular disease in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 743-753	4	
3	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018 , 36, 268-276	0.1	
2	eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. <i>HIV Research and Clinical Practice</i> , 2021 , 22, 78-85	1.7	
1	Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy.. <i>Adipocyte</i> , 2022 , 11, 143-152		